NCT02494609View on ClinicalTrials.gov

Oral Contraceptive DDI Study

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2015

Conditions
Healthy
Interventions
DRUG

sotagliflozin

400 mg sotagliflozin

DRUG

oral contraceptive

0.25 mg norgestimate/0.035 mg ethinyl estradiol

DRUG

oral contraceptive + sotagliflozin

0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin

Trial Locations (2)

47710

Lexicon Investigational Site, Evansville

75247

Lexicon Investigational Site, Dallas

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY